Cellect Biotechnology Ltd (NULL:APOP) is ranked as a Buy using the Portfolio Grader stock evaluator of Louis Navellier, which incorporates his investing methods. The current Portfolio Grader recommendation on the shares has been in place for 3 months.

Cellect Biotechnology Ltd (NULL:APOP) is one of 345 companies within the Biotechnology GICS industry group, which is in turn part of the 782 company GICS Health Care sector. APOP has a market value of $42.6 billion which is in the top decile in its industry group. The stock's current Portfolio Grader score places it 21 among the 345 companies in this industry group, putting it in the top decile; in the top quartile of the sector with a ranking of 93 among the 782 companies in the sector, and number 687 in the nearly 5,000 company Portfolio Grader universe.

Cellect Biotechnology Ltd (NULL:APOP) is a constituent of the 344 company Biotechnology GICS industry group, which is part of the 783 company GICS Health Care sector. APOP's market value is $43.5 billion which places it in the top decile in its industry group. The stock's current Portfolio Grader score places it 19 among the 344 companies in this industry group, putting it in the top decile; in the top quartile of the sector with a ranking of 84 among the 783 companies in the sector, and number 682 in the nearly 5,000 company Portfolio Grader universe.

Currently, Cellect Biotechnology Ltd (NULL:APOP) has a Buy using the Portfolio Grader stock evaluator, which incorporates Louis Navellier's investing methodology. APOP has maintained this ranking for 2 months.